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OBJECTIVE—Most knowledge on human -cell cycle control
derives from immunoblots of whole human islets, mixtures of
-cells and non--cells. We explored the presence, subcellular
localization, and function of ﬁve early G1/S phase molecules—
cyclins D1–3 and cdk 4 and 6—in the adult human -cell.
RESEARCH DESIGN AND METHODS—Immunocytochemis-
try for the ﬁve molecules and their relative abilities to drive
human -cell replication were examined. Human -cell replica-
tion, cell death, and islet function in vivo were studied in the
diabetic NOD-SCID mouse.
RESULTS—Human -cells contain easily detectable cdks 4 and
6 and cyclin D3 but variable cyclin D1. Cyclin D2 was only
marginally detectable. All ﬁve were principally cytoplasmic, not
nuclear. Overexpression of the ﬁve, alone or in combination, led
to variable increases in human -cell replication, with the
cdk6/cyclin D3 combination being the most robust (15% versus
0.3% in control -cells). A single molecule, cdk6, proved to be
capable of driving human -cell replication in vitro and enhanc-
ing human islet engraftment/proliferation in vivo, superior to
normal islets and as effectively as the combination of cdk6 plus
a D-cyclin.
CONCLUSIONS—Human -cells contain abundant cdk4, cdk6,
and cyclin D3, but variable amounts of cyclin D1. In contrast to
rodent -cells, they contain little or no detectable cyclin D2. They
are primarily cytoplasmic and likely ineffective in basal -cell
replication. Unexpectedly, cyclin D3 and cdk6 overexpression
drives human -cell replication most effectively. Most impor-
tantly, a single molecule, cdk6, supports robust human -cell
proliferation and function in vivo. Diabetes 59:1926–1936,
2010
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hile broadly similar, human pancreatic -
cells differ from their rodent counterparts in
many ways. For example, rodent -cells
can be induced to replicate using many
strategies, including partial pancreatectomy, induction of
obesity and insulin resistance, infusion of glucose, admin-
istration of growth factors, and activation of signaling
pathways downstream of these growth factors and nutri-
ents (1–8). In contrast, while evidence suggests that
human fetal and early neonatal -cells are able to replicate
(9–11), no investigator has been able to demonstrate or
induce robust rates of proliferation in adult human -cells
using the same growth factors, nutrients, signaling path-
ways, and maneuvers that have been effective in rodents
(12–19). For example, unlike events in rodents, obesity or
type 2 diabetes in human adults is not associated with
accelerated -cell proliferation (19), and even partial pan-
createctomy does not induce -cell replication or regen-
eration in humans (17). This inability to induce substantial
human -cell replication is problematic, for it is now clear
that -cell replacement therapy for diabetes will require
large numbers of human or xenogeneic -cells (20).
While much has been learned from mouse genetic
models regarding the molecular control of -cell replica-
tion (21–35), little is known regarding the molecules that
regulate the G1/S transition in the human adult -cell. We
have begun to explore these molecules in adult human
islets, mapping the members of the G1/S proteome that are
present in human cadaveric islets (12,36). Human islets are
believed to contain most of the key molecules that govern
the G1/S transition in other cell types (12,36,37). These
include the three members of the pocket protein family
(pRb, p107, and p130); cyclins D1 and D3; cdks 1, 2, 4, and
6; the four members of the INK4 family (p15, p16, p18, and
p19); the three members of the KIP/CIP family (p21, p27,
and p57); several E2F family members; and p53 and its E3
ligase, HDM2 (supplementary Fig 1, available in an online
appendix at http://diabetes.diabetesjournals.org/cgi/content/
full/db09-1776/DC1). Upstream of these G1/S molecules are
other regulatory molecules such as skp2, menin, FoxM1,
bmi1, and ezh2 (26–29,34). We and others have also shown
that human islets differ from their rodent counterparts in
that they express cdk6, a cdk that is not detectable in
mouse islets (12,35). We have also shown that overexpres-
sion of cdk6 in association with a D-cyclin, cyclin D1,
markedly increases the replication of adult human -cells
(12), and it does so in a way that does not lead to
dedifferentiation or accelerated -cell death but instead
leads to enhanced engraftment and function of adult
human cadaveric islets in vivo (12). We also have shown
that cdk4 (36) and cdk6 (12) in conjunction with cyclin D1
can enhance pRb phosphorylation and replication in hu-
man -cells. Despite these advances, it is important to
underscore that, of the 30 molecules that regulate the
human -cell G1/S transition (supplementary Fig. 1), the
therapeutic potential has been explored for only three:
cdk4, cdk6, and cyclin D1. For example, nothing is known
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and D3, in driving proliferation of human -cells.
Another difference between human and rodent islets
may involve cyclin D2. In mice, excellent evidence indi-
cates that cyclin D2 is indispensible for -cell growth and
islet development and function: animals that lack cyclin
D2 develop islet hypoplasia, hypoinsulinemia, and diabe-
tes (32,33). In contrast to mouse studies, in humans, cyclin
D2 has been reported to be difﬁcult to detect or undetect-
able, despite the use of multiple antisera from multiple
vendors and appropriate positive controls (12,37).
Here, we asked four questions. 1) Which D-cyclins are
deﬁnitively present in human islets? 2) Which of the three
D-cyclins might be the optimal partner for cdk4 or cdk6 for
enhancing adult human -cell replication? 3) Are cdk4,
cdk6, and the three D-cyclins actually present in -cells [in
contrast to immunoblot studies of whole islet extracts
described previously (12,37)], and if so, in which subcel-
lular compartment? 4) From a therapeutic standpoint, is it
essential to deliver both a D-cyclin and a cdk4/6 family
member to enhance human islet engraftment, or can this
be simpliﬁed by using only a single member of the
cdk4/6–D-cyclin complex?
We report here that 1) cyclin D1 is variably present, D2
is only marginally detectable, and D3 is readily detectable
in human islets; 2) cyclin D3 appears to be surprisingly
effective in inducing human -cell proliferation and, in
combination with cdk6, may be the most effective in
driving human -cell replication; 3) cdks 4 and 6, and
cyclins D1 and D3, are located principally in the cytoplasm
and not the nucleus; and 4) a single cdk, cdk6, is surpris-
ingly as effective in driving human islet engraftment as the
previously reported combination of cdk6 plus cyclin D1.
RESEARCH DESIGN AND METHODS
All of the methods and procedures have been described previously (5–
7,12,18,24,36). Supplementary detailed methods are available in an online
appendix. The University of Pittsburgh Institutional Review Board approved
in advance both receipt of, and work with, human islets.
RESULTS
Human islets contain easily detectable cyclin D3, but
only variable and marginal quantities of cyclins D1
and D2. The cyclin D family includes three D-cyclins,
shown schematically in supplementary Fig. 2A. As shown
in supplementary Fig. 3 (available in an online appendix),
mRNA encoding each of the three D-cyclins is present in
human islets, as assessed by conventional PCR as well as
by quantitative PCR.
Immunoblots were performed for each cyclin in adult
human islets and were compared with the expression of
the putative D-cyclin to expression in the same human
islet preps transduced with adenoviruses encoding the
corresponding D-cyclin (Fig. 1A). Human islets contain
measurable but variable amounts of cyclin D1, which was
present in 7 of 12 human islet extracts. This band was
conﬁrmed as being cyclin D1 because it was enhanced by
overexpression of cyclin D1. Importantly, no cross-reac-
tivity of this antibody was observed when cyclins D2 and
D3 were overexpressed. These results were obtained using
antibody #2,926 (Cell Signaling Technology, Danvers, MA),
and are comparable to results described by Lavine et al.
(37). Cyclin D1 was also present in several human cell
lines (HK2, SaOS2, and HKC8) and at higher levels than in
human islets in two of these (Fig. 1B).
Cyclin D3 was also easily detectable (Fig. 1A)i na l l
human islets, being present in 11 of 11 human islet
extracts, and was enhanced by adenoviral overexpression
of human cyclin D3. Again, the band was speciﬁc, because
it was intensiﬁed by overexpression of cyclin D3, and
because overexpression of the other D-cyclins did not
alter the intensity of the band. This blot was performed
using antiserum #ab28283 (Abcam, Cambridge, MA). Cy-
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FIG. 1. D-cyclins in the human islet and -cell. A: Western blot for
cyclin D1,D 2, and D3 in human islets. H1–H3 are three different human
islet preparations; H3 was transduced with the adenoviruses overex-
pressing cyclin D1 (Ad.D1), cyclin D2 (Ad.D2), or cyclin D3 (Ad.D3) to
examine cross-reactivity. Each Western blot is representative of three
different blots. Islets were extracted between 24 and 48 h of arrival or
after infection with adenoviruses. B: Immunoblots for cyclin D1,D 2,
and D3 in human cell lines and human islets. HK2, SaOS2, and HCK8 are
three human cell lines, used for more physiological levels of expres-
sion, as compared with the adenoviral overexpression. Each blot is
representative of at least three different blots. C: Subcellular localiza-
tion of cyclin D1,D 2, and D3 in human -cells. Human islets were
dispersed as described in Materials and Methods and stained for cyclin
D1,D 2,o rD 3 and insulin. Staining with no primary antibody is shown as
a negative control. D: Transduced dispersed human islets. Human islets
were dispersed and transduced with Ad.D1, Ad.D2, or Ad.D3 and stained
for each cyclin D and insulin as described in Materials and Methods. (A
high-quality digital representation of this ﬁgure is available in the
online issue.)
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human cell lines (Fig. 1B).
In contrast to immunoblots for cyclins D1 and D3, and in
contrast to results observed in PCR experiments, cyclin
D2 was barely detectable using multiple cyclin D2 antisera
in 3 of 6 human islet extracts and undetectable in 3 others,
with 1 example shown in Fig. 1A using antiserum #C7339
(Sigma, St. Louis, MO). Cyclin D2 also was difﬁcult to
detect in SaOS2 and HKC8 human cell lines, but readily
apparent in HK2 cells (Fig. 1B). Again, the antiserum was
speciﬁc, for it detected cyclin D2 when overexpressed but
not cyclins D1 or D3. These results suggest that cyclins D1
and D3 are present in human islets, but that cyclin D2, if
present, is present at very low abundance. Further, be-
cause transcripts encoding cyclin D2 are present in human
islets, the apparent lack of cyclin D2 protein may reﬂect
inhibition of translation or accelerated degradation of
cyclin D2 in human islets (31).
Cyclins D1, D2, and D3 are predominantly cytoplas-
mic in human -cells. To conﬁrm the immunoblot obser-
vations, to determine the cell type within the islet that
expresses the D-cyclins, and to determine the subcellular
locations of the D-cyclins, we performed immunoﬂuores-
cent laser confocal microscopy of single-cell suspensions
of adult human cadaveric islets. Faint cytoplasmic (and
little or no nuclear) staining was observed for cyclins D1,
D2, and D3 in most -cells (Fig. 1C). As was observed by
immunoblot, cyclin D3 was more apparent than the other
two D-cyclins.
Overexpression of the D-cyclins leads to nuclear
expression in adult human -cells. To provide positive
controls, we overexpressed the three D-cyclins and re-
peated these experiments. Bright immunoﬂuorescence
was observed when each of the three D-cyclins was
overexpressed (Fig. 1D). Interestingly, all three D-cyclins
were still primarily in the cytoplasmic compartment when
overexpressed, but nuclear staining was now easily dis-
cernable. Importantly, as shown in Fig. 1D, there was no
cross-reactivity among the three D-cyclin antisera.
cdk4 and cdk6 are easily detectable in adult human
-cells and are principally cytoplasmic. cdk4 and cdk6
are homologous members of the cdk family (supplemen-
tary Figs. 1 and 2B, available in an online appendix). To
deﬁne the subcellular localization of cdk4 and cdk6 in
human adult islets, we performed immunoﬂuorescent
studies in human islets (Fig. 2A). Both cdk4 and cdk6 were
readily detectable in human -cells, both principally in the
cytoplasm, with little or no nuclear presence. As a positive
control, overexpression of cdk4 and cdk6 resulted in
increased intensity of staining, without cross-reactivity,
but staining remained principally cytoplasmic, although
nuclear staining in a few cells is visible (Fig. 2B). As can
also be seen in this ﬁgure, immunostaining for cdk4 and
cdk6 was speciﬁc. Finally, to independently conﬁrm that
cdk4, cdk6, and cyclins D1 and D3 are principally cyto-
plasmic in human islet cells, we performed subcellular
fractionation studies in human islets (Fig. 3A, B). These
studies demonstrated that all four molecules appear in the
cytosolic fraction with the cytosolic marker, Hsp90, and
not in the nuclear fraction deﬁned by the nuclear marker,
histone 3 (H3).
Overexpression of cdk6 in combination with cyclin
D3 yields robust -cell replication. We next queried
which individual cdk4/6 or D-cyclin and which combina-
tions were most effective in driving human -cell replica-
tion. As described previously by ourselves and others
(12–19), no appreciable -cell replication was observed in
control human islets, nor in those transduced with a
control adenovirus (Ad.lacZ) (Fig. 4A). Overexpression of
the individual D-cyclins caused an obvious increase in
BrdU incorporation, and this was augmented when com-
binations of D-cyclins and cdk4 or cdk6 were used. Not
shown here, but reported previously (12,36), overexpres-
sion of cdk4 alone did not increase human -cell replica-
tion, but cdk6 overexpression was able to induce both
-cell replication as well as pRb phosphorylation.
These experiments were quantiﬁed (Fig. 4B). Combina-
tions of cdk4 and/or cdk6 with a D-cyclin were more
effective in inducing proliferation than a single D-cyclin
alone. Surprisingly, cyclin D3 in combination with cdk6
appeared to provide the largest increase in proliferation.
These results were conﬁrmed with Ki-67 (supplementary
Fig. 4A, B, available in an online appendix). Importantly,
these experiments were performed using intact human
islets, in which the inner cells within the islet were likely
not transduced, so these estimates of proliferation suggest
that further increases in proliferation would be possible if
individual -cell preparations or more efﬁcient delivery
systems were used.
cdk6 and cyclin D1 translocate to the nucleus when
overexpressed. It was unanticipated that cdks 4 and 6,
and the D-cyclins, would prove to be cytosolic. To begin to
explore the mechanisms responsible for their ability to
drive -cell replication, we examined and quantiﬁed the
nuclear presence of cdk6 when overexpressed alone, or in
combination with cyclin D1. As shown in Fig. 5A, B, when
overexpressed, cdk6 can be observed readily in the nu-
cleus, and this nuclear presence is enhanced by co-
overexpression of cyclin D1.
A single G1/S molecule, cdk6, is capable of inducing
adult human -cell replication and enhancing -cell
transplantation in vivo. The preceding studies provide
multiple combinations of cdk–D-cyclins candidates for
enhancing human -cell replacement. However, because
immunocompromised diabetic mouse/human islet trans-
plant studies—a more rigorous form of analysis—are
difﬁcult, time-consuming, and expensive, we wondered
whether a single cdk or cyclin might be sufﬁcient to
enhance human -cell engraftment and function: if one
single molecule could be shown to be effective, this might
facilitate and simplify attempts to expand human islet
mass and function. We selected cdk6 for further study,
because we had shown that the combination of cdk6 plus
cyclin D1 was effective in vivo (12), and because cdk6 is
effective alone in inducing human -cell proliferation in
vitro (12) and also led to retention of -cell function in
vitro (12). A marginal mass islet transplant of 1,500 adult
human islet equivalents (IEQ) transduced with a control
adenovirus expressing -galactosidase (Ad.lacZ) afforded
transient, marginal improvements in blood glucose in
streptozotocin-diabetic immunoincompetent NOD-SCID
mice (Fig. 6A). In contrast, 4,000 IEQ, a positive control,
normalized postprandial glucose values. As observed pre-
viously (12), 1,500 IEQ transduced with the combination of
Ad.cyclin D1 plus Ad.cdk6 performed far better than 1,500
IEQ transduced with Ad.lacZ, comparably to the 4,000 IEQ
positive control group.
There are two key novel observations in Fig. 6A. First,
1,500 human IEQ transduced with Ad.cyclin D1 alone
performed less effectively than either Ad.cdk6 alone or
Ad.cdk6 plus cyclin D1. Most importantly, 1,500 human
IEQ transduced with Ad.cdk6 alone performed as well as
cdk6 AND -CELL PROLIFERATION AND ENGRAFTMENT
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plus cyclin D1. Thus, a single cdk, cdk6, is as effective as
the combination of cdk6 plus cyclin D1 in enhancing
human islet graft function.
To more rigorously assess the function of the human
islet grafts, we performed intraperitoneal glucose toler-
ance tests three weeks after transplant (Fig. 6B). Mice
transplanted with 1,500 IEQ transduced with Ad.cdk6
displayed fasting glucose values and glucose tolerance
comparable to normal NOD-SCID mice (not treated with
streptozotocin) and to streptozotocin-diabetic NOD-SCID
mice transplanted with 4,000 IEQ, or 1,500 IEQ transduced
with Ad.cdk6 plus cyclin D1. Glucose tolerance in the
Ad.cdk6 group was superior to that in the 1,500 IEQ
Ad.lacZ or Ad.cyclin D1 groups.
Ad.cdk6 induces sustained human -cell replication
in vivo, with little cell death. We previously demon-
strated that Ad.cdk6 plus D1 induces replication in human
-cells in vivo three days after transplant (12). Here we
explored whether this early proliferation could be sus-
tained for longer periods of time. We harvested renal
capsular grafts 28 days after transplant and examined
proliferation in -cells using combined insulin and Ki-67
immunohistochemistry (Fig. 7A). Whereas little Ki-67
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FIG. 2. Subcellular localization of cdk4 and cdk6 in human -cells. A: Uninfected dispersed human islets. Human islets were dispersed as described
in Materials and Methods and stained for cdk4 or cdk6 and insulin. Staining with primary antibody and blocking peptide is shown as a negative
control. B: Dispersed human islet cells transduced with Ad.cdk4 or Ad.cdk6. Human islets were dispersed and transduced with Ad.cdk4 or Ad.cdk6
and stained for cdk4 or cdk6 and insulin as described in Materials and Methods. As can be seen, overexpressed cdk4 and cdk6 are easily
detectable, and cdk4 and cdk6 staining is speciﬁc. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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edly increased -cell Ki-67 staining is present in grafts
harvested at 28 days from islets transduced with Ad.cdk6
alone, Ad.cyclin D1 alone, and Ad.cdk6 plus Ad.cyclin D1
in combination. These observations are quantiﬁed in Fig.
7B, which shows that -cell replication rates are very low
in control grafts and remain elevated for at least 28 days
after transplant in human islets transduced with cdk6,
cyclin D1, or the combination. We also examined the islet
grafts for cdk6 immunostaining (Fig. 7C). These ﬁgures
show that cdk6 is particularly abundant in human -cells
in vivo, even 28 days after transplant, and that it is
abundant in the nuclear compartment.
-cell death, as assessed using transferase-mediated
dUTP nick-end labeling (TUNEL) staining, was barely
detectable in these grafts at 28 days, although it was easily
detectable in the positive control (Fig. 8A). We had earlier
shown that -cell death was not increased at 3 days
posttransplant (12). Because the immediate posttransplant
period is associated with cell death, and because the
engraftment response to cdk6 occurred very early post-
transplant, we also examined TUNEL staining in -cells at
24 h posttransplant (Fig. 8B, C). Again, no differences in
-cell apoptosis were observed in cdk6-expressing versus
control -cells.
DISCUSSION
We report several novel observations. First, we ﬁnd that
multiple cdk4/6 and D-cyclin combinations can robustly
stimulate human -cell replication in vitro. Surprisingly,
among all of the possible cdk4/6–D-cyclin combinations,
cyclin D3 appeared to be a particularly effective partner
for cdk6 and cdk4. Second, we demonstrate that, although
cyclin D2 is a very effective partner for both cdk4 and cdk6
in stimulating human -cell replication, and despite its
being both present and essential for rodent -cell replica-
tion and function, it is only marginally detectable in human
-cells. Third, we observe that the D-cyclins and cdks 4
and 6 are principally cytosolic proteins in the human
-cell. Fourth, we report that a single member of the
cdk4/6 D-cyclin complex, cdk6, is able to enhance human
-cell transplantation in vivo. Fifth, we demonstrate that
human -cell replication can be sustained in vivo for at
least four weeks using cdk6.
The rapid proliferation induced by the D3 combinations
(Fig. 4) was unanticipated. Of the three D-cyclins, cyclin
D2 has repeatedly been demonstrated to be essential for
mouse islet development and function, because its loss
results in early-onset diabetes (32,33). Combined loss of
both cyclins D1 and D2 accelerates this -cell failure and
diabetes, suggesting an additional or complimentary role
for cyclin D1 in the -cell (33). In human insulinoma,
cyclin D1 overexpression has been implicated etiologically
(38). In contrast, loss of cyclin D3 in mice has no apparent
effect on -cells (33,39), and no prior reports suggest a role
for cyclin D3 in human -cell physiology or therapy.
Analogously, whereas cdk4 is well known to be essential
in the rodent islet where its loss leads to diabetes and
-cell failure (23), genetic loss of cdk6 has no evident
effect on the -cell in mice (40). Indeed, normal mouse
islets are essentially cdk6 deleted (12,35). Thus, one might
have anticipated from mouse studies that cdk4 and cyclins
D1 and D2 might have been most effective in driving
human -cell replication and engraftment. These observa-
tions should be interpreted with some caution, however,
for no attempt was made to document that the actual
concentrations of the several D-cyclins and cdk4/6 were
identical when overexpressed, experiments which would
be particularly challenging to perform. Thus, while we
cannot deﬁnitively conclude that cyclin D3 is the optimal
D-cyclin partner for cdks 4 and 6 in driving human -cell
replication, the cyclin D3–cdk6 combination is particu-
larly attractive for future transplant studies.
Cyclin D2 is marginally detectable or nondetectable in
human islets by immunoblot and barely detectable in
human -cells by immunoﬂuorescence. These results cor-
roborate those by Lavine et al. (37) and were conﬁrmed by
using appropriate controls (cyclin D2 was easily observed
by immunoblot and immunohistochemistry in human is-
lets transduced with cyclin D2 adenovirus and was also
easily observed in at least one human cell line) and
multiple different antisera. This observation is interesting
for at least three reasons. First, the apparent indispens-
ability of cyclin D2 in rodent islets, in combination with its
apparent ability to markedly stimulate human -cell repli-
cation, raises the possibility that the failure of adult -cells
to generate cyclin D2 may be relevant to their inability to
replicate. Second, cyclin D2 is undetectable in human
islets despite their containing easily measurable mRNA
encoding cyclin D2. Together, these ﬁndings may indicate
that lack of cyclin D2 could play an essential role in
restraining human beta replication and suggest that cyclin
D2 and its regulation warrant further investigation in
human -cell replication, particularly at the level of pro-
tein stability as suggested by Kushner and coworkers (31).
For example, it would be interesting to examine whether
cyclin D2 is present in -cells in late embryonic or early
neonatal human life when -cells are actively replicating
(9–11). Finally, they underscore the point that mouse islet
studies do not predict with complete ﬁdelity events that
transpire in human -cells. Other well documented exam-
ples are the far lower percentage of -cells in the human
islet as compared with the rodent (41,42), the absence of
an endocrine cell mantle and more heterogeneous distri-
bution of cell types in human islet (41,42), the use of
different principal glucose transporters (Glut2 in the ro-
dent, Glut1 in the human -cell) (43–45), the lack of
proliferative responses to obesity or partial pancreatec-
D3
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Hsp 90
B
W W
FIG. 3. Subcellular fractionation of human islets. Human islets were
subcellularly fractionated into cytoplasmic fractions (C), as marked
with heat shock protein 90 (Hsp90), and nuclear fractions (N) marked
with histone 3, and compared to the initial prep of whole (W) human
islets. The three components were then immunoblotted for cyclins D1
or D3 (A) or cdk6, cdk4 (B). As can be seen, all four cdk–cyclins are
enriched in the cytosolic compartment and not detected in the nuclear
compartment. These experiments are representative of a minimum of
three human islet preparations.
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adult human -cells to proliferative mitogens and growth
factors that readily induce rodent -cell replication
(9,10,12–17,36).
The immunohistochemical subcellular localization stud-
ies were important for several reasons. First, they provide
methodology for studying cdks 4 and 6 and the D-cyclins in
human -cells. Second, they conﬁrm that this family,
which had been described in immunoblots of whole islets
previously, is present in adult human -cells. Third, they
show that all ﬁve of these molecules are principally
located in the cytoplasm, a result that was conﬁrmed by
subfractionation studies. This is surprising, because these
are generally thought to be in nuclear kinase complexes
that function by phosphorylating nuclear substrates such
as pRb. Of course, in contrast to human cancers and
mouse embryonic ﬁbroblasts, which are rapidly replicat-
ing cell types and which inform most studies on this class
of molecules, adult human -cells are typically quiescent,
failing to enter the cell cycle. That the cdk–D-cyclin family
is cytoplasmic in human -cells may provide an explana-
tion for this quiescence: their low abundance and inability
to translocate to the nuclear compartment may be rate-
limiting for adult human -cell replication. Recently, in
accord with these ﬁndings, He et al. have reported that
cyclin D2, the key D-cyclin in the mouse -cell, is also
cytoplasmic (31). It is widely believed that cdk4/6–D-
cyclins, which lack nuclear localization signals, require
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which do contain nuclear localization signals, and are
required for nuclear transit (46,47), such that inadequate
quantities of p21 or p27 could prevent nuclear access for
cdk4/6–D-cyclins. It is also possible that the Cip/Kip or
INK4 family could sequester the D-cyclin–cdk4/6 com-
plexes in the cytoplasm, preventing them from entering
the nucleus and driving proliferation. Moreover, evidence
suggests that GSK3 not only phosphorylates and targets
D-cyclins for degradation, it also may prevent nuclear
access of D-cyclins (14,31,48). Thus, it is also possible that
this or other signaling events or lack thereof, unrelated to
cell cycle inhibitors, could prevent nuclear access for
cdk4/6–D-cyclin complexes in the -cell. Equally impor-
tantly, it is clear that, when overexpressed, cdk6 can enter
the nucleus and that cooverexpression of cyclin D1 can
facilitate or enhance this process (Fig. 5A, B). Clearly, the
questions as to how and why cdks4/6 and D-cyclins appear
to remain stranded in the cytoplasm, where they are
presumably unable to phosphorylate pRb, and what regu-
lates their trafﬁcking into the nucleus of the human -cell
provide fertile ground for future study.
The in vivo transplant studies make at least two addi-
tional important and novel points. First, human -cells that
overexpress only a single G1/S molecule, in this case,
cdk6, replicate and function better than normal control
human -cells. Indeed, they also function as well as islets
that overexpress both cdk6 and cyclin D1. Second, they
replicate in vivo at high rates after transplantation, and
this replication continues for at least four weeks. This is
unaccompanied by increases in cell death and is accom-
panied by euglycemia and normal glucose tolerance, sug-
gesting that -cell differentiation is maintained despite the
marked induction of proliferation. One incompletely ad-
dressed question is “what proportion of the rapid and
sustained reduction in blood glucose in the cdk6-trans-
duced islets, and in the cdk6cyclin D1-transduced islets
in our prior study (12), is due to proliferation and in-
creased islet mass, versus enhanced -cell function (glu-
cose-sensing and insulin secretion) versus enhanced
survival?” So far, we know that proliferation is elevated at
days 3 (12) and 28 (herein). We also know that overex-
pression of cdk6 in human islets for 3 and 10 days resulted
in full retention of glucose-stimulated insulin secretion
(12). We also know that cdk6 overexpression was not
associated with increases in cell death at day 3 (12) or
days 1 or 28 posttransplant (Fig. 8). We also know that
cdk6 differs from most cdks in that it appears to have
differentiating activities in osteoblasts and prostate cells,
mediated by direct binding to differentiating transcription
factors such as Runx2 and the androgen receptor, respec-
tively (49,50). Nonetheless, it remains possible that en-
hanced survival, for example, at 6–12 h after transplant,
may be contributing to enhanced islet graft function. In
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made to quantify -cell mass in this model. Thus, it is
unknown at present precisely how cdk6 alone or in
combination enhances human islet engraftment. These
observations make cdk6 a particularly attractive target for
future longer studies in vitro and in vivo aimed at enhanc-
ing human -cell proliferation, mass, and function, as well
as at better understanding the mechanisms through which
it acts.
These studies have limitations and raise additional new
questions for future study. For example, as noted above,
they are not quantitative with regard to the absolute levels
of expression of the different D-cyclins and cdks: they
reﬂect the afﬁnity and speciﬁcity of available antisera,
which were not directly compared in strict quantitative
terms.
As another example, while we demonstrate that cdk6 is
particularly effective in vivo, we did not examine all of the
other possible cdk4/6–D-cyclin combinations: there are
some 25 potential single, double, and/or triple cdk4/6–D-
cyclin combinations that we might have explored in the in
vivo NOD-SCID diabetes model. Examining all of these
possibilities would be prohibitive with regard to time,
expense, and availability of human islets. Because we
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black lines, as described in the key within the ﬁgure. Mice transplanted
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nontransduced IEQ. The numbers in the key refer to the number of
experimental animals in each group. B: Intraperitoneal glucose toler-
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betic NOD-SCID mice transplanted with 4,000 IEQ human islets, 1,500
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digms, we elected to approach the human -cell prolifer-
ation/engraftment issue with an eye toward simpliﬁcation,
selecting a head-to-head comparison of cdk6 versus cyclin
D1. To our surprise, cdk6 alone proved to be as effective as
the combination and superior to cyclin D1 alone. Thus,
proliferation rates induced in vitro do not necessarily
predict transplant efﬁcacy in vivo: although we found
previously that combined overexpression of cdk6 plus
cyclin D1 in vitro produces far higher proliferation than
either alone, we found here that cdk6 alone produced graft
function that was comparable to the combination. This
observation was unanticipated, for during cell cycle pro-
gression, cdks remain constant, awaiting a D-cyclin part-
ner to activate their kinase activity. Thus, we had assumed
that cyclin D1 might have been rate-limiting and that cdk6
overexpression alone might have had limited effects, but
we observed the opposite. These observations raise a
number of questions, such as “what is the D-cyclin partner
that binds to cdk6 in -cells when it alone is overex-
pressed and activates proliferation?” Also, as noted above,
“is cdk6 regulation a normal checkpoint in human -cell
replication?” Another question is, “what exact cell in islet
is the target of the adenoviral cdk6?” Because cdk6
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that many cell types in addition to the -cell would be
induced to proliferate, a prediction that is supported by
our previous report (12). These cells do not appear to be
endocrine cells (12), but may be endothelial, ductal stro-
mal, mesenchymal, progenitor, or other cells. Thus, it will
be important to learn whether cdk6 overexpression using
a -cell-speciﬁc promoter leads to the same enhancement
of engraftment and function. From a therapeutic stand-
point, the implications are unequivocal: cdk6 is a particu-
larly attractive agent, both as a therapeutic molecule for
enhancing -cell replication and also as a “druggable”
target for small-molecule therapeutics that might enhance
human -cell regulation. As noted, these ﬁndings also
suggest that cdk6/cyclin D3 might also be a particularly
useful combination therapeutically.
We demonstrate that adenoviral cdk6 can drive human
-cell replication for at least 28 days in vivo. This raises
additional questions as well. For example, “how long
will/can -cell proliferation continue in this in vivo
model?” For another example, “is sustained proliferation a
good thing, or will it eventually lead to hypoglycemia or
oncogenic transformation in -cells?” Another question is,
“how long is cdk6 expression required to ensure sustained
-cell engraftment?” “Will cdk6 be required indeﬁnitely, or
can transient proliferation during the critical period of
engraftment sufﬁce to ensure long-term engraftment?” A
related question is, “can either regulated or sustained
delivery of cdk6 produce sustained human -cell replica-
tion in vitro, in a way that will permit expansion of human
-cells ex vivo with retention of differentiation?” These are
questions that should be examined in future studies in
which cdk6 is delivered using regulatable promoters.
With regard to the oncogenicity question, it is important
to recall that the G1/S family is also likely responsible for
normal human -cell proliferation in embryonic and neo-
natal life (9,10) and that they are not necessarily onco-
genes. Having said this, it would seem likely that
unregulated, long-term expression of cdk6 might have
oncogenic consequences. This concern of course applies
not only to G1/S cell cycle-activating molecules such as the
cdks and D-cyclins, but also to most mitogenic signaling
pathways, from receptors (e.g., EGF receptor, G-protein
receptors, etc.) to signaling pathways (PI3 kinase, MAP
kinase, Ras/Raf, JAK-STAT pathways, etc.) as well. Thus,
one principal goal of these studies would be to use these
strategies to identify key cellular molecules and pathways
that could be targets for small-molecule agonists. For
example, now that it is clear that cdk6 is effective individ-
ually in driving human -cell expansion, it would be
reasonable to screen small-molecule libraries to identify
molecules that activate cdk6 in human -cells. An addi-
tional goal might be to develop tools that would permit
regulated expression of G1/S molecules such as cdk6 and
D-cyclins such that they can be transiently activated to
drive -cell expansion for a few days or weeks and then
inactivated to avoid sustained -cell proliferation (51).
In conclusion, the G1/S transition is regulated by many
proteins in addition to the ﬁve studied here, as described
in the Introduction and supplementary Fig. 1. Each of
these merits future study as both a normal and a potential
therapeutic regulator of human -cell replication. The
efﬁcacy of these, alone or in combination, and whether
they may prove to be as or more effective than cdk6 as a
therapeutic target for ex vivo -cell expansion or in vivo
-cell engraftment, warrants additional study. Finally,
these studies emphasize that, while broadly similar, hu-
man and rodent -cells display differences in G1/S reper-
toires. These studies provide experimental models and
multiple targets exploiting human -cell replication, re-
placement, and engraftment in patients with diabetes.
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